Story perspectives

US Launches Section 301 Probe Over German Drug Pricing Reforms

6/19/2026

Summary

Story summary

The United States opened a Section 301 probe saying Germany’s health-care reforms undervalue American medicines.
Trade Representative Jamieson Greer said the tariff investigation will accept comments from June 25.
A public hearing is set for September 22, after which tariffs may follow.
PhRMA president Stephen Ubl welcomed probe, while German pharmaceutical industry association (VFA) lobby warned the reforms could weaken Germany’s research and access to drugs, noting that Ministry officials declined comment.

1 of 1

Story summary

The United States opened a Section 301 probe saying Germany’s health-care reforms undervalue American medicines.
Trade Representative Jamieson Greer said the tariff investigation will accept comments from June 25.
A public hearing is set for September 22, after which tariffs may follow.
PhRMA president Stephen Ubl welcomed probe, while German pharmaceutical industry association (VFA) lobby warned the reforms could weaken Germany’s research and access to drugs, noting that Ministry officials declined comment.